CARsgen Therapeutics Holdings Ltd.HKEX: 2171

Interim report 2026

· Issued by CARsgen Therapeutics Holdings Ltd. via HKEXnews

Filed with HKEX · Stock code 2171 · · 81 pages · English

Summary by 6ix AI

The report indicates that the company generated revenue primarily from its CAR T-cell product, zevorcabtagene autoleucel, and reported a net loss for the period. Additionally, the report outlines significant advancements in the company's product pipeline, including approvals and ongoing clinical trials for its therapies. The company also successfully raised funds through a placing to support its clinical development efforts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

CARsgen Therapeutics Holdings Ltd. on 6ix

Earlier from CARsgen Therapeutics

Later from CARsgen Therapeutics

All CARsgen Therapeutics news releases